Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2010

01-02-2010 | Translational Research and Biomarkers

Characterizing the HER2/neu Status and Metastatic Potential of Breast Cancer Stem/Progenitor Cells

Authors: SuEllen J. Pommier, PhD, Glenda G. Quan, MD, Dara Christante, MD, Patrick Muller, BS, Amy E. H. Newell, PhD, Susan B. Olson, PhD, Brian Diggs, PhD, Leslie Muldoon, PhD, Edward Neuwelt, MD, Rodney F. Pommier, MD

Published in: Annals of Surgical Oncology | Issue 2/2010

Login to get access

Abstract

Introduction

Treatment resistance, long latency, and high recurrence rates suggest that breast cancers arise from defective breast stem cells.

Hypothesis

Within cancers, subpopulations of cells will demonstrate differences in stem/progenitor potential, HER2/neu amplification, and gene expression. Related cells will be found in normal breast tissue.

Methods

ER-/PR-/HER2/neu + breast cancer cells were flow-sorted into subpopulations: (A) CD49f+ CD24−, (B) CD49f+CD24+, (C) CD49f CD24−, and (D) CD49f−CD24+. Gel matrix cell invasion, fluorescence in situ hybridization (FISH) HER2/neu amplification, and qRT-PCR gene expression were measured in all groups. Cells from sorted groups were implanted into rat brains. Resultant tumors were analyzed by immunohistochemistry (IHC) and FISH. Normal breast tissue was examined by IHC.

Results

Tumor development varied among sorted groups (25–75%), but was highest in group A. Tumor cells were mostly CD49f−CD24−, with variable fractions of other stem/progenitor cells. Tumors showed HER2/neu amplification, but fewer chromosome 17 per cell than inoculates. Group A tumors exhibited cells with normal chromosome 17 copy number and near normal HER2/neu amplification. Cell invasion was 61% higher in unsorted cells and 34–42% in sorted groups compared with controls. Sorted groups showed significantly different expression of development, proliferation, and invasion associated genes. In normal breast tissue, CD49f+ cells were identified in CD14+ CK19− basal epithelial layers of mammary glands; these were 95% CD24+ and 60% CD44+.

Conclusions

Breast cancer stem/progenitor cell populations differ in tumor-initiating potential but are not solely responsible for metastasis. Cancer stem/progenitor cells are less polyploid than cancer cells in general and may not be HER2/neu amplified. In normal breast tissue, breast stem/progenitor cell-like populations are present.
Literature
1.
Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMed
2.
Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821–8.PubMed
3.
Collins AT, Berrym PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.CrossRefPubMed
4.
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;6:1030–7.CrossRef
5.
O’Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.CrossRefPubMed
6.
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenetic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.CrossRefPubMed
7.
Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspective on current status and future directions: AACR Workshop of Cancer Stem Cells. Cancer Res. 2006;66:9339–44.CrossRefPubMed
8.
Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea—a paradigm shift. Cancer Res. 2006;66:1883–90.CrossRefPubMed
9.
Dontu G, al-Haij M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif. 2003;36(Suppl 1):59–72.CrossRefPubMed
10.
Dulbecco R, Henahan M, Armstrong B. Cell types and morphogenesis in the mammary gland. Proc Natl Acad Sci USA. 1982;79:7346–50.CrossRef
11.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRef
12.
Shaffee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in BRCA1/p53-mediated mouse mammary tumors. Cancer Res. 2008;68:3243–50.CrossRef
13.
Phillips TM, McBride WH, Pajonk F. The response of CD29(-/low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98:1777–85.PubMedCrossRef
14.
Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439:84-8.CrossRefPubMed
15.
Stingl J, Eirew P, Ricketson I, Shackleton M, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;1038:1–5.
16.
Jones P H, Harper S, Watt FM. Stem cell patterning and fate in human epidermis. Cell. 1995;80:83–93.CrossRefPubMed
17.
18.
Reitze RL, Valcanis H, Brooker GF, et al. Purification of a pluripotent neural stem cell from the adult mouse brain. Nature. 2001;412:736–9.CrossRef
19.
Kordon ED, Smith GH. An entire functional mammary gland may comprise the progeny from a single cell. Development. 1998;125:1921–30.PubMed
20.
Maraes RC, Zhang X, Harrington N, et al. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increase proliferation, altered differentiation and ductal dysplasia. Development. 2007;134:1231–42.CrossRef
21.
Villadsen R, Fridiricksdottir A, Ronnov-Jessen L, et al. Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol. 2007;177:87–101.CrossRefPubMed
22.
Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990;265:15286–93.PubMed
23.
Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004;82:249–93.CrossRefPubMed
24.
Gudjonsson T, Villadsen R, Nielsen HL, et al. Isolation, immortalization and characterization of human breast epithelial cell lines with stem cell properties. Genes Dev. 2002;16:693–706.CrossRefPubMed
25.
Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008;68:2419–26.CrossRefPubMed
26.
Grimshaw MJ, Cooper L, Papazisis K, et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008:10:R52.CrossRefPubMed
27.
Gotte M, Yip GW. Heparanase, Hyluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006;66:10233–7.CrossRefPubMed
28.
Mylona E, Giannopoulou I, Fasomytakis E, et al. The clinicopathologic and prognostic significance of CD44+/CD24-/low and CD44/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol. 2008;39:1096–102.CrossRef
29.
Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11:1154–9.PubMed
30.
Sheridan C, Kishimoto H, Fuchs RK, et al. CD44 +/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59.CrossRefPubMed
31.
Honeth G, Bendahl P-O, Ringner M, et al. CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53.CrossRefPubMed
32.
Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–73.CrossRefPubMed
33.
Mimeault M, Hauke R, Mehta PP, et al. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med. 2007;11:981–1011.CrossRefPubMed
34.
Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer. 2004;Res 6:R605–15.
35.
Turashvili G, Bouchal J, Burkadze G, et al. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology. 2006;73:213–23.CrossRefPubMed
36.
Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66:6063–71.CrossRefPubMed
37.
Prasad CP, Gupta SD, Rath G, et al. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between b-catenin, disheveled and cyclin D1 expression. Oncology. 2007;73:112–7.CrossRefPubMed
38.
Kikuchi A, Yamamoto H. Tumor formation due to abnormalities in the b-catenin-independent pathway of Wnt signaling. Trends Cell Biol. 2008;99:202–8.
39.
Farnie G, Clarke R. Mammary stem cells and breast cancer -role of notch signaling. Stem Cell Rev. 2007;3:169–75.CrossRefPubMed
40.
Kakarala M, Wicha M. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008;26:2813–20.CrossRefPubMed
41.
Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA. 2008;105:1680–5.CrossRefPubMed
42.
Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120–30.CrossRefPubMed
43.
Ginestier C, Hur M H, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.CrossRefPubMed
44.
Ezeh UI, Turek PJ, Reijo RA, et al. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer. 2005;104:2255–65.CrossRefPubMed
45.
Bourguignon LYW, Peyrollier K, Xia W, et al. Hyalurona-CD-44 interaction activates stem cell marker nanog, stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283:17635–51.CrossRefPubMed
46.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.CrossRefPubMed
47.
Slamon DJ, Godolphin W, Jones LA. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.CrossRefPubMed
48.
Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.CrossRefPubMed
49.
Bartlett JMS. Pharmacodiagnostic testing in breast cancer; focus on HER2 and trastuzumab therapy. Am J Pharmacogen. 2005;5:303–15.CrossRef
50.
Bartlett JMS, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422–8.CrossRefPubMed
51.
Bartlett JMS, Ibrahim M, Miller K, et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 2007;60:816–9.CrossRefPubMed
52.
Bartlett JMS, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization. When should chromosome 17 also be determined? Am J Clin Pathol 2008;130:920–6.CrossRefPubMed
53.
Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast cancer. Breast Cancer Res Treat. 2003;77:109–14.CrossRefPubMed
54.
Hanna W, O’Malley FP, Bares P, et al. Updated recommendations from the Canadian National Consensus Meeting n HER2/neu testing in breast cancer. Curr Oncol. 2007;14:149–53.CrossRefPubMed
55.
Page DL. Pathology of preinvasive and early breast cancer. Curr Opin Oncol. 1989;1:277–83.PubMed
56.
57.
Livak KJ, Schmittingen TD. Analysis of relative gene expression data using real-time quantitative PCR and 2-AACt method. Methods. 2001;25:402–5.CrossRefPubMed
58.
Latta EK, Tjan S, Parkes RK, et al. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol. 2002;15:1318–25.CrossRefPubMed
59.
Politi K, Reirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol. 2004;14:341–7.CrossRef
60.
Shakya R, Szabolcs M, McCarthy E, et al. The basal-like mammary carcinomas induced by BRCA1 or BARD1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci USA. 2008;105:7040–5.CrossRef
61.
Mills AA, Zheng B, Wang XJ, et al. P63, a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708–13.CrossRefPubMed
62.
Eigeliene N, Harkonen P, Erkkola R. Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21, p27 in cultured human breast tissues. Cell Cycle. 2008;7:71–80.PubMedCrossRef
63.
Bhargara R, Geral WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18:1027–33.CrossRef
64.
Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–13.CrossRefPubMed
65.
Yuan Z, Wong S, Borrelli A, et al. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun. 2007;362:740–6.CrossRefPubMed
66.
Purmone S, Manninen T, Pennanen P, et al. Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep. 2008;19:1627–34.
67.
Bebenek M, Dus D, Koxlak J. Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat. Adv Med Sci. 2008;53:49–53.CrossRefPubMed
68.
69.
Shin SO, Lee KH, Kim JH, et al. Alternative splicing in 5′-untranslational region of STK-15 gene, encoding centrosome associated kinase, in breast cancer cell lines. Exp Mol Med. 2000;32:193–6.PubMed
70.
Shan L, Yu M, Clark BD, et al. Possible role of stat5a in rat mammary gland carcinogenesis. Breast Cancer Res Treat. 2004;88:263–72.CrossRefPubMed
71.
You J, Mi D, Zhou X, et al. A positive feedback between activated ERK and COX/LOX maintains proliferation and migration of breast cancer. Endocrinology. 2008; doi:10.​1210/​en.​2008-0616.
72.
Bigelow RL, Williams BJ, Carroll JL, et al. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat. 2008;117:31–44. doi:10.​1007/​s10549-008-0170-7.CrossRefPubMed
73.
Suzuki T, Urano T, Miki Y, et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci. 2007;98:644–51.CrossRefPubMed
Metadata
Title
Characterizing the HER2/neu Status and Metastatic Potential of Breast Cancer Stem/Progenitor Cells
Authors
SuEllen J. Pommier, PhD
Glenda G. Quan, MD
Dara Christante, MD
Patrick Muller, BS
Amy E. H. Newell, PhD
Susan B. Olson, PhD
Brian Diggs, PhD
Leslie Muldoon, PhD
Edward Neuwelt, MD
Rodney F. Pommier, MD
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 2/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0730-z

Other articles of this Issue 2/2010

Annals of Surgical Oncology 2/2010 Go to the issue

Translational Research and Biomarkers

Enhancing Detection of Circulating Tumor Cells with Activating KRAS Oncogene in Patients with Colorectal Cancer by Weighted Chemiluminescent Membrane Array Method

Urologic Oncology

Renal Cell Carcinoma and Prognostic Factors Predictive of Survival

Melanomas

Why Does No One Want to Perform Lymph Node Dissection Anymore?

Pancreatic Tumors

Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma

Gastrointestinal Oncology

Local Excision After Preoperative Chemoradiation Results in an Equivalent Outcome to Total Mesorectal Excision in Selected Patients with T3 Rectal Cancer

Bone and Soft Tissue Sarcomas

Complete Femoral Nerve Resection with Soft Tissue Sarcoma: Functional Outcomes